MS Society responds to antibody remyelination research
The MS Society has welcomed news that US researchers at the Mayo Clinic have managed to trigger remyelination in an experimental model of multiple sclerosis (MS). This early stage research may lead to better MS treatment strategies if it can be replicated in humans.
Dr Laura Bell of the MS Society said: “Myelin repair is an exciting avenue of research that holds a lot of promise as an MS treatment, which is why we have invested more than £3million into it at our research centres in Cambridge and Edinburgh. This is an exciting study but it is early days – we'll be keen to see how it works in people with MS.”
As MS progresses, myelin repair processes fail and full function is never regained. The MS Society Cambridge Centre for Myelin Repair and Translational Research Centre in Edinburgh are both working to see if remyelination can be used to develop effective MS treatments.
Professor Franklin, Director of the MS Society Cambridge Centre for Myelin Repair said: "This is a very exciting work from the Mayo group. Clearly more research is needed to know how effectively this approach will translate in human therapy but there is every reason to be optimistic."
This kind of laboratory research needs to be translated into a treatment and extensively tested in humans in clinical trials to make sure that the method is both safe and effective.
More information about this research
BACK TO TOP
